Successful treatment of lichen planus with sulfasalazine in 20 patients by Bauza, A. (Ana) et al.
Successful treatment of lichen planus with 
sulfasalazine in 20 patients 
 
A. Bauzá, MD, A. España, MD, P. Gil, MD, P. Lloret, MD, and F. J. Vázquez Doval, MD 
  
From the Department of Dermatology, University Clinic of Navarra, Pamplona, Spain 
 
 
Correspondence: 
Agustín España, MD 
Department of Dermatology 
University Clinic of Navarra 
PO Box 4209 Pamplona 31080 Spain 
E-mail: aespana@unav.es 
 
 
 
 
 
 
 
 
 
ABSTRACT 
 
Background  
Lichen planus (LP) is a disturbing pruritic cutaneous disease that may have an spontaneous 
resolution or exhibit a more chronic course during some weeks or months.  
 
Objective  
Our objective was to demonstrate that sulfasalazine is effective in the treatment of LP. 
 
Methods  
Twenty patients were diagnosed in our department with LP of the skin and/or mucosa 
between 1985 and 2001 on the basis of clinical and histologic findings. 
 
Results  
All patients were treated with sulfasalzine at initial doses of 1.5 g/day, increasing by 0.5 
g/week to 3 g/day for 4–16 weeks. Some patients also received descendent doses for 2–12 
months. Complete responses were observed in 13 patients and partial responses in seven 
patients. All patients reported an early resolution of the pruritus. No changes were detected 
in mucosal LP. Most of the patients tolerated the treatment well and only eight patients 
presented some minor side-effects. 
 
Conclusion  
Sulfasalazine is a successful therapeutic option for cutaneous LP, constituting an 
alternative to corticosteroids and retinoids. 
  
 
 
 
 
 
Lichen planus (LP) is a common pruritic papulosquamous disorder of unknown origin 
affecting the skin and/or mucosa. Many drugs such as topical or systemic corticosteroids, 
retinoids or cyclosporinee are commonly used to treat the skin lesions, showing varying 
degrees of efficacy and side-effects.1
Sulfasalazine and the new aminosalicylates are drugs extensively used in inflammatory 
bowel disease. They are also an effective second-line therapy for rheumatoid arthritis. It is 
known that 5-aminosalicylic acid (5-ASA) is the therapeutically active fragment of 
sulfasalazine (sulfapyridine plus 5-ASA) and it has been observed that it may act, in part, 
by normalizing dysregulated arachidonic acid metabolism, especially by blocking the 
increased activity of the 5-lipo-oxygenase pathway and reducing the expression of some 
adhesion molecules and the number of intraepidermal and dermal T lymphocytes.2 This 
effect has shown to be of benefit in some dermatoses such as psoriasis.3 After a personal 
observation of the clinical improvement of cutaneous LP in a patient affected with 
inflammatory bowel disease treated with sulfasalazine, we decided to perform a 
prospective study including some patients affected with this disease. This is the first report 
of the successful response of sulfasalazine for the treatment of 20 patients affected with 
cutaneous LP. 
 
 
PATIENTS AND METHODS 
 
Twenty patients were diagnosed in our department with LP of the skin and/or mucosa 
between 1985 and 2001 on the basis of clinical and histologic findings (Table 1). All 
patients were included in a prospective study about the efficacy of the treatment with 
sulfasalazine. None of these patients received additional treatment while under 
sulfasalazine treatment. A partial response (PR) was considered when 50% or more of the 
cutaneous lesions cleared and pruritus ceased. Complete response (CR) was defined as the 
disappearance of pruritus and 100% cutaneous lesions on clinical examination, leaving 
only a residual hyperpigmentation. Patients were examined after the first 4 weeks and 
every 2 months while under treatment. A blood cell count and liver function tests were 
performed each visit. After the study, some patients kept us informed of their situation by 
phone. 
 
 
RESULTS 
 
Twenty patients affected with LP were treated with sulfasalazine for a period of 4 weeks to 
14 months. The group was composed of 11 males and nine females aged between 5 and 65 
years (mean age 41 years). The time of disease ranged from 2 weeks to 16 years (mean 
time 23 months and a half ). Ten patients had been treated beforehand with local or 
systemic corticosteroids or retinoids without any successful response. All patients were 
treated with sulfasalazine at initial doses of 1.5 g/day increasing 0.5 g per week until 3 
g/day for a period of 4–16 weeks. After the first 4–16 weeks, 11 patients also received 
decreasing doses of sulfasalazine from 3 g/day to 1 g/day for 2–12 months, reducing 0.5 
g/day every 2 or 4 weeks depending on the clinical response. Seven patients only received 
the initial increasing doses: four patients abandoned treatment because of adverse effects 
and the other three did not want to continue treatment after achieving a CR. The only child 
in the study received lower doses of 1 g/day maintained for 16 weeks followed by a further 
12 weeks of 1.25 g/day. This patient and patient 17 are still under treatment with 
sulfasalazine (Table 1). 
All patients experienced major improvement of their cutaneous lesions and reported an 
early resolution of the pruritus after 5–7 days. The final assessment of response, referred 
only to cutaneous LP and not to mucosal LP, was made when the patients obtained a CR or 
stopped the treatment. In patients 17 and 20, the assessment of response was made in the 
last visit. Complete response was obtained in 13 patients after at least 16 weeks of 
treatment. Partial response was observed in seven patients after at least 4 weeks of 
treatment (Fig. 1). No improvement was observed in the mucosal lesions in any patient. 
When treatment was discontinued, 10 patients experienced a relapse with a latency of 2 
weeks to 6 years. Five patients received further treatment with sulfasalazine after the 
relapse, and except for one patient who abandoned the treatment because of adverse effects, 
a CR was obtained in all of them (Table 1). 
Most of the patients tolerated the treatment well and only eight patients presented some 
minor side-effects, such as dyspepsia, skin rash, weakness or headache, which obligated 
five patients to abandon treatment (Table 1). One of these patients only presented side-
effects when treated with sulfasalazine for a second time. The only child in the study 
tolerated the treatment well (Fig. 2). No abnormalities were found in the laboratory tests 
other than a transient leukopenia in one patient who was not present in subsequent tests. 
 
 
DISCUSSION 
 
The use of sulfasalazine as treatment for patients with LP has never been previously 
described. We have demonstrated that oral sulfasalazine administered in increasing doses 
from 1.5 to 3 g/day for at least 4 weeks is a useful treatment for cutaneous LP but not for 
LP of the mucosa. In addition, sulfasalazine also helped in early elimination of the 
disturbing pruritus associated with LP lesions. Its efficacy was not accompanied by severe 
side-effects, and when they appeared they were reversible by reducing the dosage or 
discontinuing use of the drug. It is possible that some patients had a spontaneous remission 
of the cutaneous lesions during treatment, but the fact that three patients had a relapse only 
2 weeks after the treatment was discontinued and that four patients had a good response 
when sulfasalazine was given for a second time, supports the therapeutic effect of 
sulfasalazine in cutaneous LP. 
We do not know exactly why sulfasalazine is useful in cutaneous LP. In biopsies of LP 
lesions, large amounts of cytokines have been identified, which are produced by 
keratinocytes and tissue-infiltrated mononuclear cells.4 Some reports have demonstrated 
raised concentrations of some interleukins (IL) like IL-2, IL-6 and IL-10 in mononuclear 
infiltrates from oral LP when compared with gingival inflammatory cells. Besides, cells 
expressing m-RNA for tumor necrosis factor-α (TNF-α) and tumor growing factor-βI 
(TGF-βI) have been found in biopsies of patients with LP. These results suggest that both 
pro- and anti-inflammatory cytokines, from T-helper1 and T-helper2 cells, are generated 
simultaneously in chronic lesions of LP.5 Moreover, some adhesion molecules such as 
vascular cellular adhesion molecule 1 (VCAM-1), intercellular adhesion molecule I 
(ICAM-1)6 and E-selectin adhesion molecule I (ELAM-1)7 are expressed by Langerhans 
and endothelial cells in oral and cutaneous LP.8 Sulfasalazine is able to decrease adhesion 
molecules (VCAM, ICAM, ELAM) expression by inhibition of nuclear factor-κβ (NF- κβ) 
transcription in rat cardiac transplants.9 This drug also prevents T-helper I cells’ immune 
response by suppressing IL-12 production in macrophages and inhibits lymphocyte 
proliferative responses and IL-2 production.10 Reductions have been observed in ICAM-1 
expression, leukotriene (LTB4) synthesis and in the number of intraepidermal and dermal T 
lymphocytes, as well as T-helper CD4 cells in the skin biopsy of patients affected with 
psoriasis treated with sulfasalazine.2 We rather think that, in the same way as in psoriatic 
patients treated with sulfasalazine, the inhibition of expression of some cytokines and 
adhesion molecules could play an important role in LP. Nevertheless we do not understand 
why sulfasalazine is so useful in cutaneous LP but there is no response in the oral lesions. 
Perhaps cytokine expression is not exactly the same in these two clinical manifestations of 
the same disease. Further studies are needed to confirm this hypothesis. 
Curiously, previous reports had showed the appearance of cutaneous or oral LP as a 
complication of sulfasalazine therapy in patients with bowel inflammatory disease11 and 
rheumatoid arthritis.12
In the light of these findings, we think that sulfasalazine can be regarded as a new 
therapeutic option in the treatment of cutaneous LP, not only for its efficacy but also 
because there are no major adverse effects. It thus constitutes an interesting alternative to 
treatment with systemic corticosteroids or retinoids. 
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Figure 1. (a) Lichen planus lesions on the feet of patient 11 before treatment with 
sulfasalazine and (b) the same patient after 9 weeks of treatment, showing a partial 
response. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. (a) Papulosquamous lesions on the hips of patient 20 before treatment with 
sulfasalazine and (b) the same patient after 6 weeks of treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Follow up of patients treated with sulfasalazine 
Patient Age/ sex 
Time of
illness 
Location 
of lesions 
Time of 
treatment dose Response
Side- effects/time of 
appearance 
Treatment 
abandoned for 
adverse effects 
Relapse 
after treatment/
time of relapse 
New treatment/ 
response 
Situation at the 
end of the study 
1 53/M 2 years W, A, Mo 9 weeks ID PR Gastric pain, pruritus/8 Yes Yes P NL
2 50/M 3 years L, G 9 weeks ID PR Poor glycemic Yes No – NL
3 52/M 3 weeks L, A, C 16 weeks ID CR – No No – NL
4 56/F 2 years AF, SF 9 weeks ID CR – No Yes S 5 months/ WL
   4 months DD  3 years CR
5 61/M 16 years W, Fe, Mo 9 weeks ID PR Cutaneous rash/8 weeks Yes Yes TE OR NL
6 29/M 2 years W, Mo, G 7 weeks ID CR – No Yes S 1 year/ CR NL
7 37/M 3 months W, A, Fe, C, G 9 weeks ID CR Dyspepsia/8 weeks No Yes No NL
8 65/M 1 month L 9 weeks ID CR – No No – NL
   5 months DD  
9 59/F 7 months L 4 weeks ID CR – No No – NL
   3 months DD  
10 38/M 2 years W, Mo, G 6 weeks ID PR – No Yes TE WL
   8 months DD  2 months
11 21/F 2 weeks B, Fe, Mo 9 weeks ID CR – No No – NL
12 17/F 3 weeks A, C, B 8 weeks ID CR Dyspepsia/4 weeks No Yes S 9 months/ NL
     2 months CR
13 36/F 9 years Ge, Mo 9 weeks ID CR – No Yes S 2 months NL
   1 year DD  3 years Abandoneda
14 22/F 8 months A, H, L 8 weeks ID CR – No No – NL
   8 weeks DD  
15 61/M 3 weeks H, L 4 weeks ID PR No appetite/4 weeks No No – NL
   6 months DD  
16 50/M 8 months A, L 16 weeks ID CR – No No – NL
17 20/F 4 months Ge 12 weeks ID PR Leukopenia/8 weeks No – – WL
     S +
18 42/F 2 weeks H, F, L, B 4 weeks ID PR Fever/4 weeks Yes Yes TE WL
     2 weeks
19 53/F 4 months B, W, C, AF, IF 8 weeks ID CR – No Yes S 4 months/CR NL
20 5/M 3 months B, C, Hi 16 weeks/1 g/d CR – No – – NL S + 
    12 weeks /1.25 g/d       
W = wrists; A = arms; Mo = mouth; H = hands; B = back; AF = axillar fold; IF = inguinal fold; SF = submammary fold; C = chest; Hi = hips; L = legs; G = genitals; 
Ge = generalized; Fe = feet; PR = partial response; CR = complete response; M = masculine; F = feminine; g/d = grams/day; P = prednisone; S = sulfasalazine; TE = topical 
esteroids; OR = oral retinoids; NL = no lesions; WL = with lesions. 
ID: increasing doses of 0.5 g per week from 1 g/day to 3 g/day. 
DD: decreasing doses of 0.5 g every 2–4 weeks from 3 g/day to 1 g/day depending on the clinical response. 
aThis patient only had side-effects when she had sulfasalazine for the second time (headache and bone pain at 2 months). 
S+: Patient is still under treatment with sulfasalzine. 
